Literature DB >> 11706971

Immunopathology of secondary-progressive multiple sclerosis.

J W Prineas1, E E Kwon, E S Cho, L R Sharer, M H Barnett, E L Oleszak, B Hoffman, B P Morgan.   

Abstract

Twenty-three plaques obtained at early autopsy from 2 patients with secondary-progressive multiple sclerosis were examined immunohistochemically for microglia/macrophages, and for immunoglobulins and components of activated complement. Most of the lesions examined in both cases exhibited evidence of low-grade active demyelination of an unusual type (frustrated phagocytosis) in periplaque white matter. This included linear groups of microglia engaging short segments of disrupted myelin that were associated with deposits of C3d, an opsonin formed during complement activation. Similar microglia/C3d/myelin profiles were not observed in newly forming lesions in cases of acute multiple sclerosis or other central white matter diseases. As C3d coupling is known to increase the immunogenicity of potential antigens enormously, present findings point to disrupted myelin close to plaques as a possible source of the putative multiple sclerosis antigen. Ongoing myelin destruction found in a high proportion of old, established plaques was surprising. It suggests that slowly expanding lesions (progressive plaques), in which ongoing myelin breakdown occurs in the absence of florid perivascular cell cuffing or other histological signs of acute inflammation, contribute to disease progression in cases of secondary-progressive multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11706971     DOI: 10.1002/ana.1255

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  118 in total

1.  [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].

Authors:  M E Kornhuber; S Zierz
Journal:  Nervenarzt       Date:  2003-05-14       Impact factor: 1.214

Review 2.  Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis.

Authors:  Ales Dudesek; Uwe K Zettl
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

3.  Absence of CCL2 and CCL3 Ameliorates Central Nervous System Grey Matter But Not White Matter Demyelination in the Presence of an Intact Blood-Brain Barrier.

Authors:  Katharina Janssen; Mira Rickert; Tim Clarner; Cordian Beyer; Markus Kipp
Journal:  Mol Neurobiol       Date:  2015-02-08       Impact factor: 5.590

4.  Ultra-high-field (7.0 Tesla and above) MRI is now necessary to make the next step forward in understanding MS pathophysiology - YES.

Authors:  Francesca Bagnato; John C Gore
Journal:  Mult Scler       Date:  2016-12-16       Impact factor: 6.312

5.  Complement C3-Targeted Gene Therapy Restricts Onset and Progression of Neurodegeneration in Chronic Mouse Glaucoma.

Authors:  Alejandra Bosco; Sarah R Anderson; Kevin T Breen; Cesar O Romero; Michael R Steele; Vince A Chiodo; Sanford L Boye; William W Hauswirth; Stephen Tomlinson; Monica L Vetter
Journal:  Mol Ther       Date:  2018-08-24       Impact factor: 11.454

6.  MR imaging intensity modeling of damage and repair in multiple sclerosis: relationship of short-term lesion recovery to progression and disability.

Authors:  D S Meier; H L Weiner; C R G Guttmann
Journal:  AJNR Am J Neuroradiol       Date:  2007 Nov-Dec       Impact factor: 3.825

7.  Pathologic heterogeneity persists in early active multiple sclerosis lesions.

Authors:  Imke Metz; Stephen D Weigand; Bogdan F G Popescu; Josa M Frischer; Joseph E Parisi; Yong Guo; Hans Lassmann; Wolfgang Brück; Claudia F Lucchinetti
Journal:  Ann Neurol       Date:  2014-05-13       Impact factor: 10.422

8.  Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.

Authors:  D A Copland; K Hussain; S Baalasubramanian; T R Hughes; B P Morgan; H Xu; A D Dick; L B Nicholson
Journal:  Clin Exp Immunol       Date:  2009-12-04       Impact factor: 4.330

Review 9.  The pathological spectrum of CNS inflammatory demyelinating diseases.

Authors:  Wei Hu; Claudia F Lucchinetti
Journal:  Semin Immunopathol       Date:  2009-09-25       Impact factor: 9.623

10.  Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis.

Authors:  Susanna H Weerth; Horea Rus; Moon L Shin; Cedric S Raine
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.